Compare Mesoblast Limited (MESO) vs Roku Inc. Class A Common Stock (ROKU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Roku Inc. Class A Common Stock — how do they compare? Mesoblast Limited trades at $14.33 (market cap $1.75B), while Roku Inc. Class A Common Stock trades at $153.14 (market cap $22.84B). The key difference: Roku Inc. Class A Common Stock is far larger — about 13.1× Mesoblast Limited's market cap, and Roku Inc. Class A Common Stock is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Roku Inc. Class A Common Stock for 1 Days on average.
| MESO | ROKU | |
|---|---|---|
Market Cap | $1.75B | $22.84B |
Volume | 239,027 | 1,030,322 |
Sector | Health | Media |
52-Week High | $20.96 | $159.76 |
52-Week Low | $13.19 | $82.93 |
Typical Hold Time | 14 Days | 1 Days |
Enterprise Value | $1.83B | $20.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Roku Inc. Class A Common Stock
Roku operates a streaming platform that combines its operating system, streaming devices, TV partnerships, and advertising services. It connects viewers with streaming content and services.
Read more on ROKU →
